News from arena pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 02, 2015, 16:01 ET

Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2014 Financial Results

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full...

Feb 23, 2015, 08:00 ET

Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Monday, March 2

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00...

Feb 18, 2015, 08:00 ET

Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at...

Feb 04, 2015, 03:00 ET

Arena Pharmaceuticals GmbH annonce l'autorisation de commercialisation en Corée du Sud de BELVIQ® (hydrochlorure de lorcasérine) pour la gestion des déséquilibres de poids

-- L'autorisation déclenche un paiement d'étape de 3 millions de dollars US --  Arena Pharmaceuticals GmbH, une filiale à...

Feb 04, 2015, 03:00 ET

Arena Pharmaceuticals GmbH verkündet Zulassung für die Vermarktung von BELVIQ® (Lorcaserin HCl) als Behandlungsmittel für dauerhaftes Gewichtsmanagement in Südkorea

-- Zulassung löst Meilensteinzahlung in Höhe von 3 Millionen US-Dollar aus --  Arena Pharmaceuticals GmbH, eine...

Feb 03, 2015, 05:00 ET

Arena Pharmaceuticals Announces Marketing Approval in South Korea of BELVIQ® (lorcaserin HCl) for Weight Management

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and...

Feb 02, 2015, 08:00 ET

Arena Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the...

Jan 21, 2015, 08:45 ET

Arena Pharmaceuticals Announces Agreement to Sell Common Stock

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has sold 21,000,000 shares of common stock to Jefferies LLC and Piper Jaffray...

Jan 20, 2015, 16:04 ET

Arena Pharmaceuticals Announces Public Offering of Common Stock

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell shares of its common stock in an underwritten public...

Jan 12, 2015, 08:00 ET

Arena Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Ralinepag for Pulmonary Arterial Hypertension

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient dosing in a Phase 2 clinical trial of ralinepag, an oral,...

Jan 09, 2015, 08:00 ET

Arena Pharmaceuticals Reports on Eisai's New Marketing Initiatives for BELVIQ® (lorcaserin HCl) CIV

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported on Eisai Inc.'s updated BELVIQ® marketing program with targeted new initiatives to...

Jan 07, 2015, 08:00 ET

Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from a Phase 1b multiple ascending dose clinical trial for APD334,...

Jan 06, 2015, 08:00 ET

Arena Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 33rd...

Nov 25, 2014, 08:00 ET

Arena Pharmaceuticals Issued Composition of Matter Patent by United States Patent and Trademark Office for Ralinepag and Related Compounds

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the US Patent and Trademark Office granted Arena U.S. Patent No. 8,895,776,...

Nov 24, 2014, 08:00 ET

Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at...

Nov 13, 2014, 08:00 ET

Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at...

Nov 06, 2014, 08:00 ET

Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will...

Nov 05, 2014, 08:00 ET

Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at...

Nov 03, 2014, 06:45 ET

Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September...

Nov 03, 2014, 06:30 ET

Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin...